New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
09:55 EDTINFI, INFI, SFE, SFE, CELG, CELG, IMGN, IMGN, NVS, NVS, QSII, QSII, THOR, THORJPMorgan to host a conference
31st Annual Global Healthcare Conference is being held in San Francisco on January 7-10 with webcasted company presentations to begin on January 7 at 10 am; not all company presentations may be webcasted. Webcast Link
News For INFI;SFE;CELG;IMGN;NVS;QSII;THOR From The Last 14 Days
Check below for free stories on INFI;SFE;CELG;IMGN;NVS;QSII;THOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
08:55 EDTCELGCelgene price target raised to $115 from $100 at RBC Capital
RBC Capital increased its price target on Celgene (CELG) as the firm now estimates that the company's new oral Crohn's disease drug GED-0301 will generate $1B in sales. The firm expects Celgene's stock to rise further as it predicts that Phase II data for the company's Crohn's treatment will be much better than the data for AbbVie's (ABBV) Crohn's treatment, Humira. RBC predicts that Celgene's long-term 2020 guidance will beat expectations if the company is able to reach a legal settlement with Actavis (ACT.). RBC Capital keeps an Outperform rating on Celgene.
08:07 EDTNVSPhase 2 trial of binimetinib in NRAS melanoma shows promising clinical activity
Subscribe for More Information
07:26 EDTCELGInforma Business Information to hold a conference
Subscribe for More Information
September 26, 2014
07:30 EDTNVSNovartis drug Signifor LAR recommended by CHMP for EU approval
The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted a positive opinion for Signifor long acting release, or LAR, formulation to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue, or SSA. If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone, or GH, or insulin-like growth factor-1, or IGF-1, levels remain inadequately controlled despite treatment with currently available SSAs.
September 25, 2014
09:36 EDTCELGActive equity options trading on open
Subscribe for More Information
05:28 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies
Subscribe for More Information
September 24, 2014
13:17 EDTCELGCelgene continues rally after FDA approval of psoriasis drug
Subscribe for More Information
07:01 EDTCELGCelgene OTEZLA to become important revenue generator, says Cantor
Subscribe for More Information
September 23, 2014
15:21 EDTCELGCelgene announces FDA approves Otezla for treating plaque psoriasis
Subscribe for More Information
September 22, 2014
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
07:35 EDTTHORThoratec sees Q3 revenue $102M-$107M, consensus $109.54M
Subscribe for More Information
07:34 EDTTHORThoratec appoints Keith Grossman President and CEO
Subscribe for More Information
07:21 EDTCELGEBD Group to hold a conference
Subscribe for More Information
September 19, 2014
09:05 EDTIMGNImmunoGen discloses Chief Medical Officer James O'Leary's intention to leave
Subscribe for More Information
September 17, 2014
11:41 EDTTHORLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:00 EDTCELGConcert Pharmaceuticals announces initiation of CTP-730 Phase 1 trial
Subscribe for More Information
September 16, 2014
07:31 EDTNVSEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use